Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

BACKGROUND: Immune checkpoint inhibitors are not effective for pancreatic ductal adenocarcinoma (PDAC) as single agents. Vaccine therapy may sensitize PDACs to checkpoint inhibitor treatments. Annexin A2 (ANXA2) is a pro-metastasis protein, previously identified as a relevant PDAC antigen that is ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Victoria M., Blair, Alex B., Lauer, Peter, Foley, Kelly, Che, Xu, Soares, Kevin, Xia, Tao, Muth, Stephen T., Kleponis, Jennifer, Armstrong, Todd D., Wolfgang, Christopher L., Jaffee, Elizabeth M., Brockstedt, Dirk, Zheng, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529991/
https://www.ncbi.nlm.nih.gov/pubmed/31113479
http://dx.doi.org/10.1186/s40425-019-0601-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529991/
https://www.ncbi.nlm.nih.gov/pubmed/31113479
http://dx.doi.org/10.1186/s40425-019-0601-5

Ejemplares similares